ACT Stock Overview
Develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
AlzChem Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €56.80 |
| 52 Week High | €61.80 |
| 52 Week Low | €19.10 |
| Beta | 1.01 |
| 11 Month Change | 39.22% |
| 3 Month Change | 14.52% |
| 1 Year Change | 170.48% |
| 33 Year Change | 153.57% |
| 5 Year Change | 175.73% |
| Change since IPO | 111.23% |
Recent News & Updates
Recent updates
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year
Aug 07Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
Jul 20Shareholder Returns
| ACT | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 6.8% | -1.5% | 0.4% |
| 1Y | 170.5% | 13.2% | 14.9% |
Return vs Industry: ACT exceeded the German Chemicals industry which returned 13.2% over the past year.
Return vs Market: ACT exceeded the German Market which returned 14.9% over the past year.
Price Volatility
| ACT volatility | |
|---|---|
| ACT Average Weekly Movement | 6.9% |
| Chemicals Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ACT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ACT's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1908 | 1,607 | Andreas Niedermaier | www.alzchem.com |
AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.
AlzChem Group AG Fundamentals Summary
| ACT fundamental statistics | |
|---|---|
| Market cap | €578.02m |
| Earnings (TTM) | €46.34m |
| Revenue (TTM) | €556.77m |
12.5x
P/E Ratio1.0x
P/S RatioIs ACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACT income statement (TTM) | |
|---|---|
| Revenue | €556.77m |
| Cost of Revenue | €218.93m |
| Gross Profit | €337.84m |
| Other Expenses | €291.50m |
| Earnings | €46.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | 4.55 |
| Gross Margin | 60.68% |
| Net Profit Margin | 8.32% |
| Debt/Equity Ratio | 29.3% |
How did ACT perform over the long term?
See historical performance and comparison